AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO. (12th June 2019) - Gribben, J.; Trneny, M.; Izutsu, K.; Fowler, N.H.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; et al.